Montelukast Sodium Market Trends Are Creating New Opportunities For Industry Leaders
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Montelukast Sodium Market Expansion From $4.59 Billion In 2026 To $6.33 Billion In 2030
The market for montelukast sodium has experienced notable expansion in recent years. Projections indicate it will rise from $4.2 billion in 2025 to $4.59 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. This growth during the historical period is linked to the long-established clinical application of montelukast in managing asthma, a rising incidence of allergic respiratory conditions, a well-documented safety record for extended use, broad acceptance by healthcare providers for ongoing treatment, and the accessibility of affordable generic alternatives.
The market for montelukast sodium is forecasted to experience substantial expansion in the coming years. By 2030, its value is projected to reach $6.33 billion, driven by a compound annual growth rate (CAGR) of 8.4%. This anticipated increase over the forecast period can be attributed to a higher global prevalence of asthma and allergic rhinitis, alongside growing rates of pediatric asthma diagnoses. Other contributing factors include a heightened awareness of non-steroidal treatment options, improved access to respiratory medications in developing regions, and a sustained need for oral maintenance therapies. Key developments expected to shape this period encompass a greater reliance on leukotriene receptor antagonists for asthma control, broader use of montelukast for allergic rhinitis, and the proliferation of generic montelukast sodium options. Furthermore, a clear trend is emerging toward oral solid dosage forms for managing chronic respiratory conditions, combined with an uptick in prescriptions targeting both pediatric and adult populations.
Download A Free Sample Report For Comprehensive Market Insights:
Montelukast Sodium Market Growth Drivers And Industry Catalysts
The rising incidence of asthma is anticipated to drive expansion in the montelukast sodium market moving forward. Asthma is a chronic respiratory condition characterized by airway inflammation and narrowing, leading to recurring episodes of wheezing, shortness of breath, chest tightness, and coughing. Its prevalence is climbing due to factors such as environmental pollution, allergen exposure, genetic predisposition, urbanization, lifestyle changes, and respiratory infections. Montelukast sodium functions as a leukotriene receptor antagonist in asthma treatment, aiding in the prevention and control of symptoms by inhibiting leukotrienes, which are responsible for airway inflammation and constriction. For example, in October 2024, the National Asthma Council, an Australian non-profit organization, reported that in 2023, Australia experienced 474 asthma-related deaths—325 females and 149 males. This number closely mirrors the 473 asthma-related deaths recorded in 2022, indicating a steady pattern in asthma mortality across those two years. Consequently, the growing prevalence of asthma is fueling the montelukast sodium market’s growth.
Montelukast Sodium Market Segmentation: How Is The Market Structured Across Key Categories?
The montelukast sodium market covered in this report is segmented –
1) By Product: Crystal-like, Form-less Or Amorphous
2) By Dosage Form: Tablets, Oral Solutions
3) By Application: Bronchospasm, Allergic Coryza, Asthma, Urticaria, Other Applications
Subsegments:
1) By Crystal-Like: Monohydrate Crystal, Anhydrous Crystal, Spherical Crystals, Needle-Like Crystals, Polycrystalline Montelukast Sodium
2) By Form-Less Or Amorphous: Amorphous Powder, Amorphous Granules, Non-Crystalline Montelukast Sodium
Montelukast Sodium Market Trends Influencing Long-Term Demand
Key players in the montelukast sodium market are concentrating on creating advanced solutions, particularly combination therapies, to deliver broader relief for allergies and asthma while enhancing patient adherence. These combination treatments involve using two or more drugs together in a single regimen to target different disease pathways, leading to improved efficacy. An example of this is in October 2025, when Cadila Pharmaceuticals Ltd., a pharmaceutical firm based in India, introduced Dlorfast-M tablets. This fixed-dose combination includes desloratadine (5 mg) and montelukast (10 mg), designed to manage allergic rhinitis and urticaria. The product offers comprehensive symptom control by simultaneously acting on histamine and leukotriene pathways through a convenient once-daily oral dose. This new formulation is intended to boost patient compliance and provide sustained relief with a favorable tolerability profile.
Montelukast Sodium Market Competitive Landscape And Leading Companies
Major companies operating in the montelukast sodium market are Pfizer Inc., Merck & Co. Inc., Sanofi Aventis SA, Teva Pharmaceuticals USA Inc., Hetero Labs Ltd., Sun Pharma Industries Ltd., Aurobindo Pharma Limited, Cipla Inc., Intas Pharmaceuticals Ltd., Seqens Group, Sanyo Chemical Industries Ltd., Morepen Laboratories, Neuland Laboratories Ltd., Medopharm Private Ltd., BEC Chemicals Pvt. Ltd, Delmar Chemicals Inc., Kimia Biosciences Ltd., Ortin Laboratories Ltd., MSN Laboratories Pvt Ltd., Vamsi Labs Ltd., LGM Pharma LLC, HRV Global Life Sciences, Sigmak Lifesciences, Akums Lifesciences Ltd., Anwita Drugs & Chemicals Pvt Ltd
Access The Complete Montelukast Sodium Market Report:
Montelukast Sodium Market Geographic Landscape: Which Region Dominates Industry Growth?
North America was the largest region in the montelukast sodium market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the montelukast sodium market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
